Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
02 11 2021
Historique:
received: 20 12 2019
pubmed: 14 4 2020
medline: 11 11 2021
entrez: 14 4 2020
Statut: ppublish

Résumé

To inform proposed changes in hepatitis C virus (HCV) screening guidelines in the United States, we assessed the cost-effectiveness of HCV antenatal rescreening for women without evidence of HCV during a prior pregnancy, using a previously published model. Universal HCV rescreening among pregnant women was cost-effective (incremental cost-effectiveness ratio, $6000 per quality-adjusted life-year) and should be recommended nationally.

Identifiants

pubmed: 32282879
pii: 5819607
doi: 10.1093/cid/ciaa362
pmc: PMC8563211
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e3355-e3357

Subventions

Organisme : Gilead Sciences
Organisme : NIAID NIH HHS
ID : R01 AI147490
Pays : United States
Organisme : NIAAA NIH HHS
ID : K01 AA027733
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA023356
Pays : United States
Organisme : University of San Diego Center for AIDS Research
Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

Clin Infect Dis. 2019 Nov 13;69(11):1888-1895
pubmed: 30689769
MMWR Morb Mortal Wkly Rep. 2017 May 12;66(18):470-473
pubmed: 28493860
JAMA. 2020 Mar 10;323(10):970-975
pubmed: 32119076
J Hepatol. 2016 Jul;65(1):17-25
pubmed: 26867489
Natl Vital Stat Rep. 2019 Nov;68(13):1-47
pubmed: 32501202
Open Forum Infect Dis. 2018 Feb 17;5(3):ofy043
pubmed: 29564364
Can J Gastroenterol Hepatol. 2019 Jun 2;2019:8654741
pubmed: 31275902
Am J Med. 2018 Jan;131(1):64-71.e1
pubmed: 28807713
Obstet Gynecol. 2019 Feb;133(2):289-300
pubmed: 30633134
Ann Intern Med. 2017 Jun 6;166(11):775-782
pubmed: 28492929
Paediatr Perinat Epidemiol. 2019 Jan;33(1):O1-O4
pubmed: 30346060
Subst Abus. 2016;37(1):88-95
pubmed: 26569631

Auteurs

Antoine Chaillon (A)

Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA.

Adriane Wynn (A)

Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA.

Tatyana Kushner (T)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Nancy Reau (N)

Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.

Natasha K Martin (NK)

Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA.
Population Health Sciences, University of Bristol, Bristol, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH